We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Maxcyte Inc | LSE:MXCT | London | Ordinary Share | COM STK USD0.01 (DI) |
Price Change | % Change | Share Price | Bid Price | Offer Price | |
---|---|---|---|---|---|
-18.00 | -5.57% | 305.00 | 300.00 | 310.00 |
High Price | Low Price | Open Price | Shares Traded | Last Trade |
---|---|---|---|---|
320.00 | 305.00 | 320.00 | 13,523 | 14:57:40 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Biological Pds,ex Diagnstics | 41.29M | -37.92M | -0.3664 | -10.07 | 381.93M |
Date | Time | Source | Headline |
---|---|---|---|
10/4/2024 | 13:05 | UK RNS | MaxCyte, Inc. Notice of Results |
03/4/2024 | 07:00 | UK RNS | MaxCyte, Inc. Total Voting Rights and Block Listing Return |
02/4/2024 | 15:19 | ALNC | TRADING UPDATES: MaxCyte inks deal with Be Bio; Orcadian firms farmout |
02/4/2024 | 13:05 | UK RNS | MaxCyte, Inc. Signing of Strategic Platform License |
02/4/2024 | 07:00 | UK RNS | MaxCyte, Inc. Exercise of options and PDMR dealing |
20/3/2024 | 10:16 | UK RNS | MaxCyte, Inc. Grant of Options, RSUs and PSUs and PDMR Dealing |
20/3/2024 | 10:05 | UK RNS | MaxCyte, Inc. Grant of Options, RSUs and PSUs and PDMR Dealing |
13/3/2024 | 11:54 | ALNC | IN BRIEF: MaxCyte loss widens in 2023 as core revenue declines 25% |
13/3/2024 | 07:05 | UK RNS | MaxCyte, Inc. Filing of form 10-K for FY ended December 31, 2023 |
13/3/2024 | 07:00 | UK RNS | MaxCyte, Inc. Reports Q4 & FY 2023 Financial Results |
1 Year Maxcyte Chart |
Intraday Maxcyte Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions